Switching Between GLP-1s: Why You Start at the Bottom Again

5 min read · doses off DailyMed · last verified October 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

People move between these drugs constantly, and for good reasons: an insurer reshuffles its preferred list, side effects prove intolerable, progress stalls, or someone reaches the top of a ladder with weight still to lose.

No label covers a move from one GLP-1 drug to another. (Wegovy's label covers only switching between its own injection and tablet.) The manufacturers tested their drugs against placebo, not against each other's discontinuation. This card combines the titration rules with what endocrinologists do in practice. Use it to talk a switch through with your prescriber, not as a protocol to run yourself.

Where to start, and how long to wait

Where to start, and how long to wait
Moving fromToStart atGap
WegovyZepbound2.5 mg — the very bottomOne week
ZepboundWegovy0.25 mg — the very bottomOne week
OzempicMounjaro2.5 mgOne week
Saxenda (daily)Wegovy (weekly)0.25 mgA day — skip the next daily dose and start that week
Rybelsus (oral)Injectable semaglutide0.25 mg. The oral and injected doses are not comparable in milligrams, so there is nothing to convert.A day after the last tablet
RybelsusOzempic tablets (its US replacement)4 mg from 7 mg, 9 mg from 14 mg. The label says the two are not substitutable milligram for milligram and rules out switching during the first 30 daysThe day after the last Rybelsus tablet
OzempicWegovyCarry your dose across: same molecule, and the 0.25, 0.5 and 1 mg doses exist under both labels. Ozempic 2 mg has no Wegovy match, so ask which Wegovy dose to land on.Replace the next weekly dose
MounjaroZepboundCarry your dose across — same molecule, same strengthsReplace the next weekly dose

The last two rows are the exception. Those pairs are the same drug under a different label, so nothing about your body changes. Only the paperwork does, and that still means a fresh prescription and usually a fresh prior authorization.

Why you restart when it is the same class

After a year of doing fine, this is the instruction people are most tempted to skip.

Semaglutide and liraglutide act on the GLP-1 receptor. Tirzepatide acts on two: GLP-1 and GIP. Your gut may be thoroughly used to one of those and completely unacquainted with the other.

So someone sailing along on Wegovy at 2.4 mg with no nausea whatsoever can be floored by Zepbound at 7.5 mg, because nothing in their experience so far involved GIP. The ladder exists to introduce your digestive system to a molecule it has not met.

Why people switch

  • The formulary moved. The most common reason by far, and nothing to do with your clinical situation.
  • Not enough response at the top. Tirzepatide is a reasonable next move, and beat semaglutide when the two were compared directly.
  • Side effects that will not settle. Sometimes it is worth going the other way: dropping from tirzepatide to semaglutide removes the GIP component altogether.
  • You have run out of ladder. At the top of Saxenda, or at Wegovy's 7.2 mg maximum (for adults who have managed 2.4 mg comfortably for four weeks or longer), there is nowhere left to climb on that drug.
  • Coming off a compounded product onto the brand. Start at the brand's lowest dose unless your prescriber has the exact compounded strength and history documented, and often nobody does.

What to watch during a switch

  • Bad nausea in the first two weeks usually means the new starting dose was set too high. Drop to the bottom and climb slowly rather than pushing through.
  • Hypoglycemia if you take insulin or a sulfonylurea. A switch deserves the same caution as a first start. Sort those doses out before the first new injection, not after.
  • Never overlap two GLP-1s. If the new prescription lands before the old supply runs out, pick one. Do not bridge with both.
  • A long prior-authorization delay can turn a switch into a restart. Wegovy's label drops you back to a lower dose once two weekly doses in a row have been missed, so do not resume at your old maintenance dose. Message your prescriber instead of deciding at home.
  • Severe abdominal pain at any stage, especially reaching to the back. Stop and get seen the same day.

What this does not cover

Adults switching between GLP-1s for weight or type 2 diabetes. Not switching during pregnancy, where all of these should stop; not the surgery timing, which has its own page; not switching in children, where no standard exists; and not moving to a non-GLP-1 weight drug, which is a different decision altogether.

Where to go next

References

  1. 1.U.S. National Library of Medicine — DailyMed. WEGOVY (semaglutide) injection — Structured Product Label. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.U.S. National Library of Medicine — DailyMed. ZEPBOUND (tirzepatide) injection — Structured Product Label. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  3. 3.U.S. National Library of Medicine — DailyMed. OZEMPIC (semaglutide) injection — Structured Product Label. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  4. 4.U.S. National Library of Medicine — DailyMed. MOUNJARO (tirzepatide) injection — Structured Product Label. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  5. 5.Aronne LJ, Horn DB, le Roux CW, et al.; SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. PMID: 40353578.
  6. 6.U.S. National Library of Medicine — DailyMed. RYBELSUS and OZEMPIC (semaglutide) tablets — Structured Product Label. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98

Frequently Asked Questions

2.5 mg, the lowest step, with about a week between the last Wegovy injection and the first Zepbound one. Your time on semaglutide does not carry across, because tirzepatide also acts on the GIP receptor and your gut has no experience of that.
Roughly one weekly dosing interval (a week) between two weekly drugs. Coming off daily Saxenda you can simply skip the next daily dose and begin the new drug that week, and coming off oral Rybelsus a day is enough. What you must never do is take both at once to smooth the transition.
Because tolerance is specific to the molecule rather than to the class. Semaglutide and liraglutide work through the GLP-1 receptor alone; tirzepatide works through GLP-1 and GIP. Someone comfortable on Wegovy at its full dose has never exposed their gut to GIP activation, and starting tirzepatide mid-ladder on the strength of that comfort is how people end up violently unwell.
No. That pair is the same molecule under two labels, and the 0.25, 0.5 and 1 mg doses exist under both, so your dose comes straight across and you simply replace the next weekly injection. Mounjaro to Zepbound works the same way. The exception is Ozempic 2 mg, which has no Wegovy equivalent; your prescriber picks the landing dose. You will still need a new prescription and probably a new prior authorization, because the paperwork changes even though nothing in your body does.
A short gap is a switch; a long one is a restart. Wegovy's label treats two skipped weekly doses in a row as a reason to restart the climb lower down, so after a gap that long, do not pick up at your previous maintenance dose. Your tolerance for the gastrointestinal effects will have faded even though your prescription has not. Message your prescriber and re-titrate rather than resuming where you left off.

Editorial reference content, not medical advice. Changing a dose, holding one, or stopping altogether is a decision for you and your prescriber together. As for the numbers: we checked every dose figure here against the FDA-approved Structured Product Label on DailyMed in October 2026.

Browse all cheat sheets, top-N research lists, or long-form research deep-dives.